Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Study sponsor: Eikon Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2035-12Estimated
Enrollment · participants740Estimated
Source updated2026-10-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.